WARF: P05197US

Method for Reducing Intraocular Pressure Using Integrin-Linked Kinase Inhibitor


Donna Peters, Jennifer Faralli

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a method of treating increased intraocular pressure by administering agents that interfere with activities of integrin-linked kinase.
OVERVIEWIntegrin-linked kinase (ILK) is an intracellular protein that plays an important role in connecting integrins to the actin cytoskeleton. UW-Madison researchers have shown that ILK works with phosphatidylinositol 3-kinase (PI3K) to regulate the organization of the actin cytoskeleton in trabecular meshwork cells in the eye, which control the outflow of fluid from the aqueous humor to modulate intraocular pressure. When fluid cannot flow normally from the aqueous humor, intraocular pressure increases and elevates the risk of developing glaucoma.
THE INVENTIONUW-Madison researchers now have developed a method of treating increased intraocular pressure by administering agents that interfere with activities of integrin-linked kinase. Interfering with the ability of ILK to couple integrin signaling to the actin cytoskeleton increases aqueous humor outflow through the trabecular meshwork and decreases intraocular pressure. A PI3K inhibitor can be administered with the ILK inhibitor to further reduce intraocular pressure.
  • Preventing or treating glaucoma
  • Reduces elevated intraocular pressure
  • Treatment is non-invasive.
For More Information About the Inventors
Contact Information
For current licensing status, please contact Rafael Diaz at or 608-960-9847.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.